FR06C0021I2 - Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire - Google Patents
Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaireInfo
- Publication number
- FR06C0021I2 FR06C0021I2 FR06C0021C FR06C0021C FR06C0021I2 FR 06C0021 I2 FR06C0021 I2 FR 06C0021I2 FR 06C0021 C FR06C0021 C FR 06C0021C FR 06C0021 C FR06C0021 C FR 06C0021C FR 06C0021 I2 FR06C0021 I2 FR 06C0021I2
- Authority
- FR
- France
- Prior art keywords
- nucleic acid
- acid ligand
- growth factor
- vascular endothelial
- endothelial growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/739,109 US5859228A (en) | 1995-05-04 | 1996-10-25 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US08/870,930 US6168778B1 (en) | 1990-06-11 | 1997-06-06 | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US08/897,351 US6051698A (en) | 1997-06-06 | 1997-07-21 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
PCT/US1997/018944 WO1998018480A1 (fr) | 1996-10-25 | 1997-10-17 | Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire |
Publications (2)
Publication Number | Publication Date |
---|---|
FR06C0021I1 FR06C0021I1 (fr) | 2006-10-13 |
FR06C0021I2 true FR06C0021I2 (fr) | 2007-08-03 |
Family
ID=27419245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR06C0021C Active FR06C0021I2 (fr) | 1996-10-25 | 2006-07-03 | Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP1685842A3 (fr) |
JP (2) | JP3626503B2 (fr) |
KR (1) | KR100514929B1 (fr) |
AT (1) | ATE318143T1 (fr) |
AU (1) | AU733674B2 (fr) |
CA (1) | CA2269072C (fr) |
DE (3) | DE69735292T2 (fr) |
DK (1) | DK0957929T3 (fr) |
ES (1) | ES2259188T3 (fr) |
FR (1) | FR06C0021I2 (fr) |
GE (1) | GEP20094799B (fr) |
IL (2) | IL129497A0 (fr) |
LU (1) | LU91252I2 (fr) |
NL (1) | NL300234I2 (fr) |
NZ (1) | NZ334859A (fr) |
PT (1) | PT957929E (fr) |
RU (1) | RU2177950C2 (fr) |
WO (1) | WO1998018480A1 (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US6346611B1 (en) * | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
US6232071B1 (en) * | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
US6762290B1 (en) * | 1999-07-29 | 2004-07-13 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
AU782620B2 (en) * | 1991-06-10 | 2005-08-11 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
CZ2002140A3 (cs) * | 1999-07-14 | 2002-05-15 | Alza Corporation | Neutrální lipopolymer a lipozomové kompozice, které jej obsahují |
EP2351855A1 (fr) * | 2000-09-26 | 2011-08-03 | Duke University | Aptamères d'ARN et leurs procédés d'identification |
EP2431377B1 (fr) * | 2001-10-26 | 2017-04-19 | Noxxon Pharma AG | Acide nucléique L modifié |
EP1441743A4 (fr) * | 2001-11-09 | 2009-02-25 | Eyetech Pharmaceuticals | Procedes destines a traiter des neoformations de vaisseaux sanguins oculaires |
US7767803B2 (en) | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
CA2492463A1 (fr) | 2002-07-25 | 2004-02-05 | Archemix Corporation | Compositions therapeutiques aptameriques regulees |
US9303262B2 (en) | 2002-09-17 | 2016-04-05 | Archemix Llc | Methods for identifying aptamer regulators |
US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
EP1570085A4 (fr) * | 2002-12-03 | 2007-07-25 | Archemix Corp | Methode de selection in vitro d'acides nucleiques 2'-substitues |
FR2852606A1 (fr) * | 2003-03-18 | 2004-09-24 | Inst Nat Sante Rech Med | Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie |
CA2523260A1 (fr) | 2003-04-21 | 2004-11-04 | Archemix Corporation | Aptameres stabilises lies a un facteur de croissance derive de plaquette et leur utilisation en tant qu'agents therapeutiques d'oncologie |
CL2004001996A1 (es) * | 2003-08-08 | 2005-05-06 | Eyetech Pharmaceuticals Inc | Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion. |
EP3385384B1 (fr) | 2004-02-12 | 2020-04-08 | Archemix LLC | Agents thérapeutiques à base d'aptamères utiles dans le traitement de troubles liés au complément |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
JP2007532662A (ja) * | 2004-04-13 | 2007-11-15 | (オーエスアイ)アイテツク・インコーポレーテツド | 高分子量の立体的な基へ抱合された核酸アプタマー |
US7579450B2 (en) | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
EP3034089A1 (fr) | 2004-11-02 | 2016-06-22 | Archemix LLC | Aptameres stabilises pour plaquettes derives du facteur de croissance et leur utilisation en tant que produits therapeutiques oncologiques |
WO2007005645A2 (fr) | 2005-06-30 | 2007-01-11 | Archemix Corp. | Materiaux et procedes pour la generation de transcriptions d'acide nucleiques modifiee en 2' |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
JP2009510182A (ja) * | 2005-07-28 | 2009-03-12 | (オーエスアイ)アイテツク・インコーポレーテツド | シクリトールリンカーポリマー抱合体 |
US20090324551A1 (en) | 2005-08-22 | 2009-12-31 | The Regents Of The University Of California Office Of Technology Transfer | Tlr agonists |
KR100877824B1 (ko) | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | E2epf ucp-vhl 상호작용 및 그 용도 |
TW200804425A (en) * | 2005-12-06 | 2008-01-16 | Domantis Ltd | Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor |
WO2007069068A2 (fr) * | 2005-12-16 | 2007-06-21 | Diatos | Conjugués peptidiques de pénétration cellulaire pour la délivrance d'acides nucléiques dans une cellule |
JPWO2007080902A1 (ja) * | 2006-01-11 | 2009-06-11 | 協和発酵キリン株式会社 | 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤 |
EP1991275B1 (fr) | 2006-03-08 | 2014-11-05 | Archemix LLC | Aptamères de liaison du complément et agents anti-c5 utiles dans le traitement de troubles oculaires |
PL2125007T3 (pl) | 2007-02-07 | 2014-07-31 | Univ California | Koniugaty syntetycznych agonistów TLR i ich zastosowania |
US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
JP5971948B2 (ja) * | 2008-12-04 | 2016-08-17 | クルナ・インコーポレーテッド | Vegfに対する天然アンチセンス転写物の抑制による血管内皮増殖因子(vegf)関連疾患の治療 |
KR101800833B1 (ko) | 2009-03-20 | 2017-11-23 | 씨엘에스엔 래버러토리스, 인코퍼레이티드 | 폴리아민 유도체 |
EP2504436A1 (fr) | 2009-11-23 | 2012-10-03 | INSERM - Institut National de la Santé et de la Recherche Médicale | Aptamères dirigés contre la protéine de matrice 1 de virus de la grippe de type a et leurs utilisations |
AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
CA2811601A1 (fr) * | 2010-09-24 | 2012-03-29 | Mallinckrodt Llc | Conjugues d'aptameres pour ciblage de nanovecteurs therapeutiques et/ou diagnostiques |
US20150337308A1 (en) | 2012-04-11 | 2015-11-26 | Chu De Bordeaux | Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
EP2912182B1 (fr) | 2012-10-23 | 2021-12-08 | Caris Science, Inc. | Aptamères et leurs utilisations |
AU2013361323B2 (en) | 2012-12-19 | 2018-09-06 | Caris Science, Inc. | Compositions and methods for aptamer screening |
WO2014148638A1 (fr) | 2013-03-22 | 2014-09-25 | 国立大学法人東京大学 | Aptamère pour il-17 et utilisation de celui-ci |
KR20220061248A (ko) | 2013-07-12 | 2022-05-12 | 이베릭 바이오, 인크. | 안과적 질환을 치료하거나 예방하기 위한 방법 |
JP2016533752A (ja) | 2013-08-28 | 2016-11-04 | カリス ライフ サイエンシズ スウィッツァーランド ホー | オリゴヌクレオチドプローブおよびその使用 |
PL3230316T3 (pl) | 2014-12-11 | 2022-05-02 | Bayer Healthcare Llc | Leczenie zwyrodnienia plamki żółtej związanego z wiekiem z małą aktywną zmianą neowaskularyzacji naczyniówki |
RU2723032C2 (ru) | 2014-12-29 | 2020-06-08 | Бонак Корпорейшн | Композиция, стабильно содержащая молекулу нуклеиновой кислоты |
AU2016229076B2 (en) | 2015-03-09 | 2022-01-20 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
US10590425B2 (en) | 2015-06-29 | 2020-03-17 | Caris Science, Inc. | Therapeutic oligonucleotides |
AU2016298317B2 (en) | 2015-07-28 | 2021-02-18 | Caris Science, Inc. | Targeted oligonucleotides |
WO2017046140A1 (fr) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Régimes de traitement de dr et rvo en fonction de l'étendue de l'ischémie rétinienne |
JP2019516393A (ja) | 2016-03-18 | 2019-06-20 | カリス サイエンス インコーポレイテッド | オリゴヌクレオチドプローブおよびその使用 |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
AU2017271579B2 (en) | 2016-05-25 | 2023-10-19 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
EP3332812A1 (fr) | 2016-12-07 | 2018-06-13 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ensemble à base d'acide nucléique et utilisation de l'ensemble dans la thérapie du cancer |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
JP7163288B2 (ja) | 2017-07-04 | 2022-10-31 | 第一三共株式会社 | 視細胞変性を伴う網膜変性疾患用薬 |
WO2019210097A1 (fr) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamères ayant une stabilité, une puissance ou une demi-vie pour une sécurité et une efficacité améliorées |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0462145B1 (fr) * | 1989-03-07 | 1994-04-27 | Genentech, Inc. | Conjugue covalent de lipides et d'oligonucleotides |
US5459015A (en) * | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US5849479A (en) * | 1990-06-11 | 1998-12-15 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
-
1997
- 1997-10-17 RU RU99110377/04A patent/RU2177950C2/ru active
- 1997-10-17 WO PCT/US1997/018944 patent/WO1998018480A1/fr active IP Right Grant
- 1997-10-17 DE DE69735292T patent/DE69735292T2/de not_active Expired - Lifetime
- 1997-10-17 CA CA002269072A patent/CA2269072C/fr not_active Expired - Lifetime
- 1997-10-17 DE DE200612000029 patent/DE122006000029I2/de active Active
- 1997-10-17 PT PT97912811T patent/PT957929E/pt unknown
- 1997-10-17 IL IL12949797A patent/IL129497A0/xx unknown
- 1997-10-17 NZ NZ334859A patent/NZ334859A/xx not_active IP Right Cessation
- 1997-10-17 KR KR10-1999-7003488A patent/KR100514929B1/ko not_active IP Right Cessation
- 1997-10-17 AU AU49904/97A patent/AU733674B2/en not_active Expired
- 1997-10-17 ES ES97912811T patent/ES2259188T3/es not_active Expired - Lifetime
- 1997-10-17 EP EP06003279A patent/EP1685842A3/fr not_active Withdrawn
- 1997-10-17 GE GEAP199711120A patent/GEP20094799B/en unknown
- 1997-10-17 DK DK97912811T patent/DK0957929T3/da active
- 1997-10-17 EP EP97912811A patent/EP0957929B1/fr not_active Expired - Lifetime
- 1997-10-17 JP JP52055398A patent/JP3626503B2/ja not_active Expired - Lifetime
- 1997-10-17 DE DE1997635292 patent/DE122006000029I1/de active Pending
- 1997-10-17 AT AT97912811T patent/ATE318143T1/de active
-
1999
- 1999-04-19 IL IL129497A patent/IL129497A/en not_active IP Right Cessation
-
2004
- 2004-10-15 JP JP2004301813A patent/JP4160038B2/ja not_active Expired - Lifetime
-
2006
- 2006-06-14 LU LU91252C patent/LU91252I2/fr unknown
- 2006-07-03 FR FR06C0021C patent/FR06C0021I2/fr active Active
- 2006-07-20 NL NL300234C patent/NL300234I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
DK0957929T3 (da) | 2006-07-03 |
PT957929E (pt) | 2006-06-30 |
JP3626503B2 (ja) | 2005-03-09 |
CA2269072C (fr) | 2006-02-14 |
KR100514929B1 (ko) | 2005-09-15 |
KR20000052697A (ko) | 2000-08-25 |
IL129497A (en) | 2009-06-15 |
FR06C0021I1 (fr) | 2006-10-13 |
AU733674B2 (en) | 2001-05-24 |
JP4160038B2 (ja) | 2008-10-01 |
JP2005046160A (ja) | 2005-02-24 |
AU4990497A (en) | 1998-05-22 |
DE69735292D1 (de) | 2006-04-27 |
EP1685842A2 (fr) | 2006-08-02 |
LU91252I2 (fr) | 2006-08-14 |
EP0957929A1 (fr) | 1999-11-24 |
DE122006000029I1 (de) | 2006-10-19 |
EP1685842A3 (fr) | 2006-11-29 |
CA2269072A1 (fr) | 1998-05-07 |
DE69735292T2 (de) | 2006-10-19 |
RU2177950C2 (ru) | 2002-01-10 |
IL129497A0 (en) | 2000-02-29 |
NZ334859A (en) | 2001-02-23 |
NL300234I1 (nl) | 2006-09-01 |
ES2259188T3 (es) | 2006-09-16 |
EP0957929A4 (fr) | 2003-06-25 |
ATE318143T1 (de) | 2006-03-15 |
EP0957929B1 (fr) | 2006-02-22 |
DE122006000029I2 (de) | 2007-11-08 |
GEP20094799B (en) | 2009-10-26 |
NL300234I2 (nl) | 2006-10-02 |
JP2001505191A (ja) | 2001-04-17 |
WO1998018480A1 (fr) | 1998-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR06C0021I2 (fr) | Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire | |
ATE452136T1 (de) | Nukleinsäureligand-komplexe | |
CY1114352T1 (el) | Συμπλοκα συνδετηρων νουκλεϊνικου οξεος παραγοντα αναπτυξης που λαμβανεται απο αιμοπεταλιο (pdgf) | |
DE69109131T2 (de) | Verfahren zur herstellung von molekularsieben, einschliesslich zeolithen, mit metallchelat-komplexen. | |
DE69002137T2 (de) | Magnetische lager. | |
GR3008515T3 (fr) | ||
DE69017398T2 (de) | Buschmäher. | |
DK0705846T3 (da) | Höjmolekylære og lavmolekylære fraktioner af von Willebrand-faktor | |
DE59001438D1 (de) | Verfahren zur herstellung von tetrabrom-4,4'-alkyliden-diphenolen. | |
FI893428A0 (fi) | Eliminering av toxiska egenskaper in vitro och in vivo hos tnf-a medelst monoklonala antikroppar och fragment haerledda fraon dessa. | |
ES2063326T3 (es) | Conjugados de polimixina. | |
DE60045577D1 (de) | Von willebrand-faktor-aktivitätsnachweis | |
DE69101708T2 (de) | Verfahren zur herstellung von übergangsmetallnitridkomplexen. | |
DK0570575T3 (da) | Bicykloazamakrocyklophosphonsyre, komplekser, konjugater, kontrastmidler og fremstilling heraf | |
DE69806164T2 (de) | Verfahren zur herstellung von polyanilin mit hohem molekulargewicht in seiner emeraldinform | |
DE59001106D1 (de) | Verfahren zur herstellung von 1,1,1-trifluor-2-chlorethan. | |
DE3875512D1 (de) | Dufterzeugnis mit gesteuerter abgabe und verfahren zu seiner herstellung. | |
DE59008750D1 (de) | Verfahren zur Herstellung von Ironen. | |
DE3880991T2 (de) | Aminoanthracendion-bis-platinkomplexe, nützlich als Antitumor-Agenzien. | |
DE69012103D1 (de) | Verfahren zur herstellung von 4,4'-diisopropylbiphenyl. | |
IT8720256A0 (it) | Complessi di b- ciclodestrina adattivita' antimicotica. | |
DE59804233D1 (de) | Verfahren zur Herstellung von Formylimidazolen | |
DE59002719D1 (de) | Ringkernlager zur Abstützung von Antriebsaggregaten in Kraftfahrzeugen. | |
SI0957929T1 (sl) | Kompleksi liganda nukleinske kisline vaskularnegaendotelijskega rastnega faktorja (VEGF) | |
DE59106957D1 (de) | Verfahren zur herstellung von trans-3,3,5-trimethylcyclohexylethylether. |